placeholder image
T. Battelino All authors
About
Publications While At HealthPartners
selected publications
Journal Article
  • Expert panel recommendations for a standardized ambulatory glucose profile report for connected insulin pens. 
    Diabetes Technology & Therapeutics. 2024
  • CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. 
    Cardiovascular Diabetology. 2023
  • Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. 
    Endocrine Reviews. 2023
  • Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomized controlled InRange trial. 
    Diabetes, Obesity & Metabolism. 2023
  • Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. 
    The lancet. Diabetes & endocrinology. 2022
  • Impact of temporary glycemic target use in the hybrid and advanced hybrid closed-loop systems. 
    Diabetes Technology & Therapeutics. 2022
  • Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. 
    Cardiovascular Diabetology. 2022
  • A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. 
    Lancet (London, England). 2021
  • Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. 
    Diabetologia. 2021
  • The digital/virtual diabetes clinic: the future Is now-recommendations from an international panel on diabetes digital technologies introduction. 
    Diabetes Technology & Therapeutics. 2021
  • Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). 
    Pediatric Diabetes. 2020
  • Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). 
    Diabetologia. 2020
  • InRange: comparison of the second-generation basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring-study design. 
    Diabetes Therapy. 2020
    • Editorial Article
  • Continuous glucose monitoring-derived data report-simply a better management tool [editorial]. 
    Diabetes care.  43. 2020
    • Conference Poster
  • CGM-based clinical targets: recommendations from the International Consensus on Time-in-Range (TIR) [poster]
    2019
    • Review
  • Continuous glucose monitoring and metrics for clinical trials: an international consensus statement [review]. 
    The lancet. Diabetes & endocrinology. 2023
  • Comparison of second-generation basal insulin analogs: a review of the evidence from continuous glucose monitoring [review]. 
    Diabetes Technology & Therapeutics. 2021
  • Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time-in-Range [review]. 
    Diabetes care. 2019
  • International consensus on use of continuous glucose monitoring [review]. 
    Diabetes care. 2017
    • Contact
    full name
  • T. Battelino
    • Quick Info
     
    Collaboration